Secondary Central Nervous System Lymphoma

Secondary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 9
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 22%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03703167	Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)	completed	Phase 1	25	Memorial Sloan Kettering Cancer CenterOTHER	1	Jan 29, 2026	clinicaltrials

Data updated 22 days agoSource updated Jan 29, 2026source: clinicaltrials